PSC
Patient Square Capital Portfolio holdings
AUM
$277M
1-Year Return
6.76%
This Quarter Return
+15.38%
1 Year Return
+6.76%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$277M
AUM Growth
+$35.7M
(+15%)
Cap. Flow
+$4.8M
Cap. Flow
% of AUM
1.73%
Top 10 Holdings %
Top 10 Hldgs %
90%
Holding
22
New
3
Increased
3
Reduced
10
Closed
3
Top Buys
| 1 |
argenx
ARGX
|
$16M |
| 2 |
Insmed
INSM
|
$2.87M |
| 3 |
Geron
GERN
|
$1.01M |
| 4 |
Cidara Therapeutics
CDTX
|
$731K |
| 5 |
Allogene Therapeutics
ALLO
|
$302K |
Top Sells
| 1 |
Liquidia Corp
LQDA
|
$6.26M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$3.41M |
| 3 |
Intellia Therapeutics
NTLA
|
$1.66M |
| 4 |
Soleno Therapeutics
SLNO
|
$1.33M |
| 5 |
EyePoint Pharmaceuticals
EYPT
|
$1.22M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$8.82B
| $141M | 50.71% |
12,480,000
| – | – |
|
|
2
Insmed
INSM
$30.7B
| $36.1M | 13.02% |
358,800
+28,550
| +9% | +$2.87M |
|
|
3
argenx
ARGX
$45.9B
| $16M | 5.76% |
+29,000
| New | +$16M |
|
|
4
EyePoint Pharmaceuticals
EYPT
$966M
| $12.7M | 4.59% |
1,352,837
-129,140
| -9% | -$1.22M |
|
|
5
Liquidia Corp
LQDA
$2.48B
| $12.7M | 4.58% |
1,020,000
-502,452
| -33% | -$6.26M |
|
6
Ocular Therapeutix
OCUL
$2.37B
| $7.59M | 2.74% |
817,699
-102,500
| -11% | -$951K |
|
7
Cullinan Oncology
CGEM
$413M
| $6.54M | 2.36% |
868,897
-10,000
| -1% | -$75.3K |
|
8
Kymera Therapeutics
KYMR
$3.11B
| $6.11M | 2.2% |
140,000
-2,201
| -2% | -$96.1K |
|
9
Mirum Pharmaceuticals
MIRM
$3.82B
| $5.77M | 2.08% |
113,462
-2,900
| -2% | -$148K |
|
10
Scholar Rock
SRRK
$3.02B
| $5.45M | 1.97% |
154,000
| – | – |
|
11
Enliven Therapeutics
ELVN
$1.19B
| $4.93M | 1.78% |
245,838
-8,000
| -3% | -$160K |
|
12
Nurix Therapeutics
NRIX
$758M
| $4.7M | 1.69% |
412,296
-35,000
| -8% | -$399K |
|
13
Agios Pharmaceuticals
AGIO
$2.09B
| $4.65M | 1.68% |
139,732
| – | – |
|
14
Pharvaris
PHVS
$1.48B
| $4.3M | 1.55% |
244,283
-1,213
| -0.5% | -$21.3K |
|
15
Disc Medicine
IRON
$2.11B
| $3.92M | 1.41% |
74,000
-9,000
| -11% | -$477K |
|
|
16
Allogene Therapeutics
ALLO
$255M
| $2.98M | 1.07% |
2,635,000
+266,814
| +11% | +$302K |
|
|
17
Geron
GERN
$893M
| $1.01M | 0.36% |
+716,000
| New | +$1.01M |
|
|
18
Cidara Therapeutics
CDTX
$1.6B
| $731K | 0.26% |
+15,000
| New | +$731K |
|
19
VYNE Therapeutics
VYNE
$7.62M
| $523K | 0.19% |
317,033
+60,000
| +23% | +$99K |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| – | – |
-38,500
| Closed | -$3.41M |
|
|
21
Intellia Therapeutics
NTLA
$1.29B
| – | – |
-232,781
| Closed | -$1.66M |
|
|
22
Soleno Therapeutics
SLNO
$3.71B
| – | – |
-18,600
| Closed | -$1.33M |
|